YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Zymeworks Inc. Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI® expected to contribute immediately accretive revenu…
[Reciprocal Tariffs] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - SEPTEMBER 14 * VOLATILITY WAT…
It has been about a month since the last earnings report for Theravance Biopharma (TBPH). Shares have added about 0.8% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend contin…
Theravance Biopharma TBPH reported second-quarter 2026 adjusted earnings of 19 cents per share, matching the Zacks Consensus Estimate. In the year-ago quarter, the company had incurred an adjusted loss of 8 cents per share. Total revenues…
Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring item…
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurri…
Shares of Theravance Biopharma TBPH sank by around 3% on June 29, 2026, after the company announced a definitive agreement with Zymeworks Inc. ZYME under which the latter will acquire TBPH in an all-cash transaction valued at approximately…
Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m (C$1.32bn). Under the terms of the deal, Theravance Biopharma shareholders will receive $1…
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Theravance Biopharma TBPH reported first-quarter 2026 adjusted earnings of 1 cent per share, beating the Zacks Consensus Estimate of breakeven earnings. In the year-ago quarter, the company had incurred an adjusted loss of 17 cents per sha…
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
Corcept Therapeutics CORT incurred a first-quarter 2026 loss of 30 cents per share, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had reported earnings of 17 cents per share. First-quarter revenues rose 4.…
Laughing Water Capital, an investment management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Class A investment in Laughing Water Capital returned approximately -4.5% net of al…
Theravance Biopharma, Inc. (NASDAQ:TBPH) is one of the most undervalued biotech stocks to buy right now. B. Riley lifted the price target on Theravance Biopharma, Inc. (NASDAQ:TBPH) to $17 from $14 on April 7, reiterating a Neutral rating…
Shares of Theravance Biopharma TBPH have plunged nearly 17% over the past three months against the industry’s growth of 2.2%. The steep decline follows a major setback involving its lead pipeline candidate, ampreloxetine, a once-daily nore…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary l…
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or “the Compan…
For Immediate Release Chicago, IL – April 6, 2026 – Today, Zacks Equity Research discusses Indivior Pharmaceuticals INDV, Catalyst Pharmaceuticals CPRX, Theravance Biopharma TBPH, Relmada Therapeutics RLMD and Avalo Therapeutics AVTX. Indu…
The drug and biotech sector has been in a recovery mode since mid-2025, after going through a difficult period between 2021 and 2023 backed by strong quarterly results, surging mergers and acquisitions (M&A) activity and pipeline and regul…
Theravance Biopharma TBPH reported fourth-quarter 2025 adjusted earnings of 6 cents per share, which missed the Zacks Consensus Estimate of 44 cents. In the year-ago quarter, the company had incurred an adjusted loss of 5 cents per share.…
Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026 Strategic Review Committe…
[Red arrow And dollar finance decline graph- Stock image] Baris-Ozer Theravance Biopharma (TBPH [https://seekingalpha.com/symbol/TBPH]) announced on Tuesday that it will halt its clinical program for its rare disease therapy ampreloxetine…
CorMedix CRMD and Theravance Biopharma TBPH occupy a similar niche in the market as small-cap biopharmaceutical companies working to turn promising science into sustainable revenues. Both companies, having a market cap of less than $1 bill…
Irenic Capital Management cut its stake in Surgery Partners(NASDAQ:SGRY) by 1,047,583 shares in the fourth quarter, an estimated $19.25 million trade based on quarterly average pricing, according to a February 17, 2026, SEC filing. What ha…
Irenic Capital Management LP disclosed a new stake in Alkami Technology(NASDAQ:ALKT) in its February 17, 2026, SEC filing, adding 2,106,448 shares in a trade estimated at approximately $48.60 million based on quarterly average pricing. Wha…
On February 17, 2026, Irenic Capital Management LP disclosed a new position in Integer Holdings(NYSE:ITGR), acquiring 1,263,663 shares in an estimated $99.11 million trade based on quarterly average pricing. What happened According to an S…
Key Points Irenic Capital acquired 452,066 shares of SPS Commerce in the fourth quarter. The quarter-end position value for SPS Commerce was $40.29 million, reflecting a new position established in the quarter. This new position places SPS…
On February 17, 2026, Newtyn Management bought 1.6 million shares of Vistance Networks(NASDAQ:VISN) in the fourth quarter. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Newtyn Managem…
On February 17, 2026, Newtyn Management disclosed a buy of 350,000 shares of Array Digital Infrastructure(NYSE:AD), an estimated $17.3 million trade based on quarterly average pricing. What happened According to an SEC filing dated Februar…
Key Points Newtyn Management bought 2,906,420 NVRI shares in the fourth quarter; the estimated trade size was $43.31 million based on quarterly average prices. Meanwhile, the quarter-end position value increased by $60.94 million, reflecti…
Newtyn Management reported a buy of 2,906,420 shares of Enviri Corporation(NYSE:NVRI) in its February 17, 2026, SEC filing, an estimated $43.31 million transaction based on average quarterly pricing. What happened According to a SEC filing…
On February 17, 2026, Newtyn Management disclosed a new position in Integer Holdings(NYSE:ITGR), acquiring 550,000 shares worth an estimated $43.14 million. What happened According to an SEC filing dated February 17, 2026, Newtyn Managemen…
According to an SEC filing dated Feb. 17, Irenic Capital Management LP reduced its position in Papa John's International(NASDAQ:PZZA)by 748,592 shares. The fund’s remaining stake, reported at quarter-end, was 325,108 shares worth $12.51 mi…
(RTTNews) - Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment. Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, u…
A month has gone by since the last earnings report for Theravance Biopharma (TBPH). Shares have lost about 3.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings releas…
Key Points New York City-based Newtyn Management sold 807,135 shares of Millrose Properties, reducing its position by $23 million in the third quarter. The transaction represented approximately 2.8% of reported 13F assets under management.…